Branched-chain keto acid dehydrogenase kinase deficiency
A genetic disorder causing low BCAA levels and neurodevelopmental deficits.
Branched-chain keto acid dehydrogenase kinase deficiency (BCKDK deficiency) is caused by mutations in the BCKDK gene. The body breaks down branched-chain amino acids (BCAAs) too quickly, resulting in low levels of these essential nutrients. This leads to impaired brain development, which can manifest as intellectual disability, autism spectrum disorder, and epileptic seizures.
Signs and symptoms include autism, intellectual disability, and developmental delay. A study of 20 cases reported neurodevelopmental delay, impaired gross motor function, intellectual disability, language impairment, epilepsy, clumsiness, and microcephaly that is not present at birth.
Treatment involves continuously replenishing BCAA levels, often combined with a high-protein diet. Ongoing research suggests that supplementing every three hours may yield greater improvement. In one treatment regimen (100–260 mg/kg/day of BCAA plus a high-protein diet), all patients showed improved motor function, and half achieved normal head circumference. None of the patients who began treatment before age two developed autism, and one patient who started treatment at eight months experienced nearly normal development by age three.
As of 2020, only 21 cases have been documented worldwide. The disease was first described in 2012 in three unrelated families. A 2013 study by García-Cazorla, Oyarzabal et al. confirmed that BCKDK mutations cause neurobehavioral deficits and supported dietary intervention, showing that BCAA supplementation every three hours plus a high-protein diet led to significant improvement.
- key study cohort
- 20 cases reported by García-Cazorla, Oyarzabal et al.
Lore & Background
The disease was first described in 2012 in three unrelated families. Later, García-Cazorla, Oyarzabal et al. confirmed that BCKDK mutations can result in neurobehavioral deficits in humans and supported the rationale for dietary intervention. In their 2013 study, they found BCAA supplementation every 3 hours plus a high protein diet showed significant improvement.
Reader's Guide
BCKDK deficiency is a rare autosomal recessive disorder that disrupts branched-chain amino acid metabolism, leading to their accelerated breakdown. This deficiency causes low BCAA levels, which are essential for brain development. The condition manifests as intellectual disability, autism spectrum disorder, epilepsy, and motor impairments. Treatment with BCAA supplementation and a high protein diet has shown promise: in one study, all patients improved in motor functions, half reached normocephaly, and none who started treatment before age 2 developed autism. The earliest-treated patient (8 months) experienced near-normal development at age 3. Ongoing studies suggest that more frequent supplementation (every 3 hours) may yield greater improvement. With only 21 documented cases worldwide, BCKDK deficiency remains a very rare but treatable cause of neurodevelopmental delay.
Did You Know?
- The disease was first described in 2012 in three unrelated families.
- Treatment with BCAA supplementation (100–260 mg/kg/day) plus a high protein diet improved motor functions in all patients in one study.
- None of the patients who started treatment before 2 years old developed autism.
- The patient who started treatment at 8 months experienced almost normal development at 3 years old.
More in Genetic diseases and disorders 1-24
Spotted an error? Know more?
This is a living reference — every entry is fact-audited, and reader corrections feed straight into our audit queue. Suggest an edit · See this site's audit record